|
OpenBiome is a nonprofit organization in Boston, Massachusetts which operates a public stool bank and spurs cutting-edge research in the microbiome. OpenBiome distributes material to hospitals and clinics to support the treatment of ''C. difficile'', the most common pathogen causing hospital-acquired infection in the U.S. OpenBiome operates the world's largest stool bank, providing frozen preparations of screened and filtered human stool for use in Fecal Microbiota Transplantation (FMT) therapies. OpenBiome can provide clinicians with three different formulations: a high-concentration "FMP 30" formulation for upper delivery, a lower-concentration "FMP 250" for lower delivery, and, as of October 2015, a capsule formulation. As of October 2015, OpenBiome had provided over 6,000 treatments to 49 states and 7 nations. OpenBiome's research arm investigations into the use of FMT to treat ''C. difficile'' and other indications, such as irritable bowel syndrome and Crohn's disease. OpenBiome is involved in a large number of ongoing clinical trials on FMT as a restorative microbial therapy. OpenBiome is currently involved in a dose-finding study for its encapsulated formulation.〔https://clinicaltrials.gov/ct2/show/NCT02403622〕 Separately, OpenBiome also provides stool samples to research partners for investigations into the microbiome and future therapeutics. Recently, OpenBiome announced the launch of PersonalBiome,〔http://www.openbiome.org/personalbiome/〕 a stool banking program through which individuals could store their stool for future use in fecal transplantation after microbial dysbiosis.〔http://www.nytimes.com/2015/10/11/opinion/sunday/should-we-bank-our-own-stool.html?action=click&pgtype=Homepage&module=opinion-c-col-right-region®ion=opinion-c-col-right-region&WT.nav=opinion-c-col-right-region&_r=1〕 OpenBiome was founded in 2012 by Mark Smith, a microbiology PhD student at MIT, and James Burgess, an MBA student at the MIT Sloan School of Management. It is the first public stool bank, and was founded to facilitate clinical adoption of FMT. The logistical burdens associated with screening and processing fecal material have historically made it difficult for clinicians to offer FMT to patients with recurrent ''C. difficile'' infections despite its relative efficacy (94% cure rate compared to 31% with the antibiotic Vancomycin). Openbiome operates as a 501(c)3 nonprofit organization based in Medford, MA. ==Publications== * () * () 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「OpenBiome」の詳細全文を読む スポンサード リンク
|